TMED2

Across TCGA pan-cancer cohorts, TMED2 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated TMED2 data layer compared with 26 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher TMED2 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated TMED2 expression acts as an unfavorable survival marker, although some lineages such as HNSC show a favorable association.

CCRCC, LUAD, and LSCC are the cancer types where TMED2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	OS	Median	All	0.656	1.000	.006	22	view →
LUAD	DFS	Median	II,III,IV	0.741	1.000	.001	14	view →
LSCC	OS	Tertile	II,III,IV	0.609	0.942	.010	9	view →
PDAC	DFS	Tertile	All	0.693	0.858	.010	3	view →
HNSC	OS	Median	III,IV	0.912	0.811	.014	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

TMED2–CCRCC (OS)

Open the CCRCC breakdown →